Achaogen prices upsized IPO at $12, the low end of the range

By
A A A

Achaogen, which is developing antibiotic treatments for multi-drug resistant infections, raised $72 million by offering 6.0 million shares at $12, at the low end of the $12 to $14 range. Insiders that previously indicated an intent to purchase up to 25% of the deal size did not buy on the offering. Achaogen, which now commands a fully diluted market cap of $211 million, will list on the NASDAQ under the symbol AKAO. Credit Suisse and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: AKAO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Can You Talk Sexy Money?
Can You Talk Sexy Money?            

Stocks

Referenced

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com